When Teva Pharmaceutical Industries disclosed last week that it had purchased a stake in its reluctant acquisition target, local generic drug maker Mylan, the strategy behind the investment wasn’t entirely clear.
The Israeli generic drug behemoth, which now owns 1.6 percent of Mylan’s shares, has had little to say. But according to one expert, the move could help Teva attract support for its spurned, $82-per-share takeover offer made in April.
The fact that Cecil-based Mylan reincorporated in the Netherlands earlier this year is a key factor in the situation. Under corporate law in that country, Teva may now have a number of options that could help it win Mylan’s hand.
For starters, as a shareholder, Teva could attend Mylan’s special shareholders meeting — tentatively set for late July or early August — when stockholders would be asked to approve the acquisition of over-the-counter medication specialist Perrigo.
Mylan’s bid for Perrigo, which Perrigo’s board has rejected, has been seen as a way for Mylan to bulk up enough to thwart Teva. If Mylan stockholders approve the transaction, Mylan has said it then plans to take the offer directly to Perrigo shareholders.
At the Mylan meeting, Teva could vote its shares and “can talk to the other shareholders and the board of directors of Mylan” to try to win support for the Teva-Mylan merger or to vote against the Perrigo transaction, said Martijn Kesler, a corporate law expert with the law firm AMS Advocaten based in Amsterdam.
Read More
If Teva can accumulate enough additional shares or team up with other like-minded large shareholders, the company could put a proposal on the agenda, Mr. Kesler said.
According to Mylan’s new bylaws, one or more shareholders representing at least 3 percent of Mylan’s shares can submit a proposal.
“Timing is crucial,” Mr. Kesler said, because proposals must be submitted at least 60 days prior to the meeting.
He said one proposal might be for Teva to ask shareholders to dismantle Mylan’s “stichting” provision, a Dutch-style poison pill aimed at helping the company block a hostile takeover.
“It’s not unthinkable that the board of Mylan refuses” any Teva proposal, Mr. Kesler said.
In that case, Teva could petition the courts for a spot on the agenda.
Another, perhaps more likely strategy, would be for Teva to challenge the poison pill in court.
“The manner in which anti-takeover schemes are used can … be assessed by the court,” Mr. Kesler wrote in an article last month discussing the Mylan-Teva situation.
In Mylan’s case, the company reincorporated in the Netherlands not only to cut its corporate tax bill “but also specifically to implement antitakeover schemes,” he wrote. “All of this to stay out of the hands of Teva.”
Mylan did not respond to emails Thursday seeking comment.
In early April, as talk swirled that Teva was considering a bid, Mylan’s board set up the stichting plan.
A Dutch court would evaluate whether activating a poison pill is “contrary to reasonableness and fairness,” Mr. Kesler said.
Under certain circumstances, Teva also could call a special meeting of Mylan shareholders. Dutch law allows one or more shareholders holding at least 10 percent of a company’s shares to request that the court convene such a meeting.
Teva revealed last month it had acquired 1.35 percent of Mylan’s shares. The company recently purchased additional shares, bringing its stake to 1.6 percent, and reportedly is poised to buy more. A Teva spokeswoman this week declined comment.
Analyst Corey Davis with Canaccord Genuity in New York City said accumulating at least a 4.6 percent stake would give Teva more standing in Dutch court to challenge the stichting.
By taking a major stake, “Teva is likely sending Mylan shareholders a message, ‘We are serious about pursuing Mylan. We are lining up to go to Dutch court. We are not going anywhere,’ ” Mr. Davis said in an email.
He said Teva might be expected to sweeten its half stock/half cash bid for Mylan in the next two to three weeks, ahead of the special shareholders meeting.
“While a bump from $82 would be nice, an increase in cash and a regulatory reverse termination fee are more important,” Mr. Davis said.
The latter would address worries that a Mylan-Teva combination would be rejected by the U.S. Justice Department on antitrust concerns.
According to Mr. Kesler, the Mylan-Teva-Perrigo maneuvering has drawn considerable interest in the Netherlands.
“Everybody is waiting” to see what happens next, he said.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.